Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
544 articles with Emergent BioSolutions
-
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
1/9/2022
Emergent BioSolutions Inc. announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021.
-
Drug Screening Market Size to Reach USD 13.56 Billion in 2027 Growing at a CAGR of 17.1%, according to Emergen Research
1/3/2022
According to Emergen Research, the global drug screening market size was USD 3.83 Billion in 2019 and is expected to reach USD 13.56 Billion in 2027 and register a revenue CAGR of 17.1% during the forecast period, 2020-2027.
-
Emergent BioSolutions is to Participate in Investor Conferences
1/3/2022
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022.
-
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
12/16/2021
Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate.
-
Health Canada announces results of Emergent BioSolutions facility inspection
11/24/2021
Health Canada has completed its onsite inspection of the Emergent BioSolutions facility in Baltimore, Maryland . The European Medicines Agency and South African Health Products Regulatory Authority also participated in this inspection remotely.
-
Emergent BioSolutions Announces Stock Repurchase Program - Nov 11, 2021
11/11/2021
Emergent BioSolutions Inc. announced that its Board of Directors has authorized management to repurchase up to $250 million of the company's common stock from time to time on the open market or in privately negotiated transactions.
-
The U.S. government canceled a contract with Maryland-based Emergent BioSolutions, which earlier in the year ruined about 15 million doses of the Johnson & Johnson COVID-19 vaccine.
-
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
11/4/2021
Emergent BioSolutions Inc. reported financial results for the third quarter ended September 30, 2021.
-
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA's signal to start shipping the vaccines.
-
COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.
-
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
9/14/2021
Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development
-
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
8/25/2021
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease.
-
Emergent BioSolutions to Participate in Investor Conferences - Aug 23, 2021
8/23/2021
Emergent BioSolutions Inc. announced that members of the company’s senior management team will participate in the following investor conferences:.
-
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
-
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
7/29/2021
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance.
-
COVID News: EUA Expanded for Baricitinib, Emergent Starts to Manufacture J&J Vaccine Again and More
7/29/2021
As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir. -
A recent report suggests that cross-contamination is not all that uncommon of an issue, and maybe inevitable.
-
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
7/15/2021
Emergent BioSolutions Inc. will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.
-
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s COVID-19 vaccine, Emergent is now facing a shareholder lawsuit accusing the company of insider trading.
-
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.